Gemcitabine alone is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. Lead sponsors include West China Hospital (1) and Shenzhen University General Hospital (1). Registered phase: Phase 2. Conditions studied include Locally Advanced Thyroid Gland Carcinoma; Thyroid Cancer; Pancreatic Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06234072 | Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients (ClinicalTrials.gov ↗) Pancreatic Cancer |
Phase 2 | Not yet open |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (ClinicalTrials.gov ↗) Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced Thyroid Gland Carcinoma | 1 |
| Thyroid Cancer | 1 |
| Pancreatic Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| West China Hospital | 1 |
| Shenzhen University General Hospital | 1 |
| Register | Gemcitabine alone trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine alone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine alone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.